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1. Introduction  
Matrix metalloproteinases (MMP) constitute a family of 23 zinc- and calcium-dependent 
endopeptidases that play pivotal functions in several physiological processes such as 
embryogenesis, wound healing, vasculogenesis or stem cell mobilization (Nagase et al., 
2006). These enzymes were originally defined as matrix-degrading proteases, but a myriad 
of other substrates have been discovered including cytokines, chemokines, growth factors 
and their receptors, cell adhesion molecules and angiogenic factors. MMP were first 
described to exert their degradative function extracellularly against matrix macromolecules 
or at the pericellular microenvironment. Recently, MMP proved to cleave intracellular 
substrates belonging to any subcellular compartments (Cauwe & Opdenakker, 2010). 
Among them were notably apoptotic regulators, signal transducers, molecular chaperones 
or transcriptional and translational regulators. Therefore, MMP can be considered as 
proteases mainly controlling signaling events through processing cytokines, chemokines 
and degrading matrix, liberating matrikines in the extracellular space, or in turn cleaving 
enzymes involved in signal transduction inside the cells. MMP are regulated at distinct 
levels including gene expression, compartmentalization, proenzyme activation, enzyme 
inhibition, endocytosis, and finally substrate availability and affinity. MMP up-regulation 
participates in tumor progression and metastasis, inflammatory disorders, cardiovascular 
and autoimmune diseases (Hu et al., 2007; López-Otín & Matrisian, 2007; Mandal et al., 
2003; Murphy & Nagase, 2008). 
All MMP are produced as proenzymes i.e. zymogen; enzyme latency is due to the 
formation of a coordinated bond between the zinc atom in the active site and an amino 
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acid residue cysteine present in a consensus PRCGXPD sequence in MMP prodomain. 
Proteolysis of the prodomain, action of reactive oxygen species (O2
, NO) on the amino 
acid residue cysteine and allosteric perturbation (Sela-Passwell et al., 2010) of the 
prodomain can disrupt this Cys-Zn bond, a process named “cysteine switch” (Van Wart & 
Birkedal-Hansen, 1990). In the active enzyme, the zinc atom is linked to three histidine 
residues and a water molecule. A conserved glutamic acid residue (Glu) in the catalytic 
domain HEBXHXBGBXHS polarizes the water molecule (Gomis-Rüth, 2009; Lovejoy et al., 
1994). This ligated water molecule attacks the carbonyl carbon of the scissile bond and 
transfers a proton to Glu and then to the scissile nitrogen atom. Then Glu releases the 
second proton from the water molecule to the scissile nitrogen atom and the peptide bond 
is cleaved (Figure 1). 
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Fig. 1. Mechanism of action of MMP (adapted from Lovejoy et al., 1994). 
Historically, MMP were named according to their preferential action on matrix components: 
collagenases (MMP-1, MMP-8, MMP-13), gelatinases (MMP-2, MMP-9), proteoglycanases or 
stromelysins (MMP-3, MMP-10), macrophage elastase (MMP-12). 
To date, a classification based on their domain organization is favoured: five of them are 
secreted and the others are transmembrane proteins (MT-MMP) based on their structure 
similarities (Table 1) (Egeblad & Werb, 2002).  
MMP family is constituted by: a pre-domain involved in enzyme secretion, a pro-domain 
including a cysteine residue interacting with the zinc atom in the catalytic domain that 
maintains the inactive enzyme form. The catalytic domain is responsible of the MMP 
activity. All MMP, except MMP-7, MMP-26 (28 kDa) and MMP-23 (56 kDa) possess a 
hemopexin-like domain involved in the substrate interactions. The gelatinases (MMP-2 (72 
kDa) and MMP-9 (92 kDa)) contain a gelatin-binding type II domain with three fibronectin 
(Fn(II))-like repeats. MMP-11 (51 kDa) and MMP-28 (59 kDa) contain a furin motif for 
recognition by furin-like serine proteinases. This motif is also present in MMP containing a 
vitronectin-like domain (MMP-21 (70 kDa)) and membrane-type MMP (MT-MMP). In 
addition, MT-MMP have a transmembrane domain and a short cytoplasmic domain or a 
glycosylphosphatidylinositol anchored (MMP-17 (57 kDa) and MMP-25 (63 kDa)). Finally, 
MMP-23 is a type II transmembrane MMP with a cysteine array and immunoglobulin-like 
domain. 
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Designation Main structure Name 
MMP-7 
MMP-26 Pre P ro
S H
Z nc a ta ly tic M in im a l -d om a in
Matrilysin 
Matrilysin-2 
MMP-1 
MMP-3 
MMP-8 
MMP-10 
MMP-12 
MMP-13 
MMP-18 
MMP-19 
MMP-20 
Pre P ro
S H
Z nc a ta ly tic
S S
h em o pe x in
S im ple h em op exin -dom a in
Collagenase-1 
Stromelysin-1 
Collagenase-2 
Stromelysin-2 
Metalloelastase 
Collagenase-3 
Collagenase-4 
 
Enamelysin 
MMP-2 
MMP-9 
P re P ro
S H
Z nc a ta ly tic
S S
F nF n F n
he m o pe x in
G ela tin b in d ing
 
Gelatinase A 
Gelatinase B 
MMP-11 
MMP-28 
Pre Pro
S H
Znc ata lyt ic
S S
F u
h em o pe x in
F ur in ac tiv a ted
 
Stromelysin-3 
Epilysin 
MMP-14 
MMP-15 
MMP-16 
MMP-24 
Pre P ro
S H
Znc a ta lyti c
S S
F u Tm
h e m op ex i n
C y T rans m em b ra ne
 
MT1-MMP 
MT2-MMP 
MT3-MMP 
MT5-MMP 
MMP-17 
MMP-25 
P re Pro
SH
Z nca ta ly tic
S S
F u
G PI
he m o pe x in
GP I-a nch ored
MT4-MMP 
MT6-MMP 
MMP-21 P re P ro
S H
Z nc a ta lyti c
S S
FuVn
he m op e x in
Vi tronec tin -l ik e
 
XMMP 
(Xenopus) 
MMP-23 
Pre Pro ca ta ly ticF u C A Ig - l ik e T ype II trans m em brane
 
Femalysin 
Table 1. MMP family. Pre: signal peptide, Pro: propeptide, Fn: fibronectin type II domain, 
Fu: furin recognition site, Vn: vitronectin-like domain, TM: transmembrane domain,  
Cy: cytoplasmic domain, GPI: glycosylphosphatidylinositol, CA: cysteine array, Ig-like: 
immunoglobulin-like domain. 
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2. Structures and properties of gelatinases 
2.1 Structure of gelatinases active sites 
Gelatinases A (MMP-2) and B (MMP-9), as classified as both collagenases and elastases, are 
involved to a great extent in pathologies affecting major elastic tissues (lung, arteries). 
Among the MMP family members, gelatinases subclan, MMP-2 and MMP-9, do exhibit 
several originalities that could be taken into account for the design of inhibitors. 
MMP family proved to have a great homology of sequence and the zinc-containing catalytic 
site is surrounded by subsite pockets named S1, S2, S3 for non-primed and S’1, S’2, S’3 for 
the primed side (Terp et al., 2002).   
The conserved amino acid residues in gelatinases active-site region (Cuniasse et al., 2005; 
Kontogiorgis et al., 2005; Nicolotti et al., 2007; Rao, 2005) are given in Table 2. 
The structural amino acid sequence of MMP is mainly similar except for the loop region (S’1 
pocket), which displays different length and is composed of distinct amino acid 
composition. The similarities are ordered as S’1 > S2 > S’3 > S1, S3 > S’2. 
Selective and/or combined occupancy of these pockets were believed to direct selectivity of 
inhibitor. More generally, it has been determined that such subsites display distinct potency 
in driving selectivity in order S’1 > S2, S’3, S3 > S1 > S’2.  
S’1 pocket located immediately to “the right” of the catalytic site differs notably in size and 
shape among MMP and has been named specific pocket. 
The S’1 pocket is deep, presenting an elongated and hydrophobic shape with an amino acid 
residue Leu at position 197 for all MMP except MMP-1 and MMP-7. The variation of amino 
acid residues among MMP, within this pocket, might be important. It adopts an extended 
shape in both gelatinases, but S’1 pocket in MMP-2 forms a large channel nearly bottomless, 
while it is slightly flexible in MMP-9 presenting a real pocket-like subsite. 
The S’2 pocket is shallow, partly solvent-exposed and delimited on the top face by the 
amino acid residue 158 and on the bottom face by the amino acid residue 218. Its size is 
affected by the amino acid residues 162 (Asn), which is a Leu for both gelatinases, 163 (Val) 
which is an Ala for both gelatinases and 164 (Leu).  
The S’3 pocket is neutral and partly solvent-exposed and delimited by the amino acid 
residues 222 (Leu) and 223 (Tyr). The size of this pocket is dependent on the amino acid 
residue 193, which is a Tyr for both gelatinases (Table 2). 
As a rule, the substrates bind weakly with the unprimed subsites; however, some 
differences could be assigned between gelatinases. 
The S1 pocket is shallow and hydrophobic. The same triad is pinpointed for MMP-2 and 
MMP-9 (His166-Phe168-Tyr155 and His183-Phe185-Tyr172, respectively). The amino acid 
residue 163 and to a lower extent the amino acid residue 155 influence the S1 subsite 
interactions with an inhibitor. The amino acid residue 163 is a Leu for both gelatinases. 
The S2 pocket is solvent-exposed and the amino acid residues 86, 169 and 210 are poorly 
conserved in MMP family and affect the shape and the properties of this pocket. Its shape is  
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Table 2. Overview of favorable ligand properties and conserved domains of gelatinases 
(adapted from Cuniasse et al., 2005; Nicolotti et al., 2007; Terp et al., 2002). 
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dependent on the amino acid residue Pro at the position 87, then the MMP-2 has its Phe87 
leading to a small and hydrophobic pocket and MMP-2 interacts with positive charge 
probes. When the Pro87 is lacking, another conformation was observed. The amino acid 
residue at the position 169 is a Pro for MMP-9 and defines a large hydrophobic pocket.  
Finally, the amino acid residue 210, Asn in MMP-9 and Glu in MMP-2, leads to a less 
exposed pocket and notably plays a crucial role in enzyme selectivity. The S2 pocket is 
important and differentiates both gelatinases.  
The S3 pocket is composed of a hydrophobic cleft delimited by the amino acid residues 155 
and 168. The pocket shape and size are influenced by the amino acid residue 155 which is a 
Tyr and 168 which is a Phe for both gelatinases. 
Although these subsites might direct enzyme specificities, interaction of gelatinases with 
macromolecular substrates also relies on the presence of remote binding sites named 
exosites that also notably act in driving enzyme action (Figure 2). 
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Fig. 2. Functions of gelatinases domains. 
2.2 Biological properties of gelatinases  
Gelatinases are most often associated to the cell plasma membrane of normal or transformed 
cells, thus targeting the proteolytic activity of invasive cells. Enzyme tethering to cell 
periphery requires the carboxy terminal hemopexin-like domain, designated as PEX of 200 
amino acid residues on average forming a four bladed -propeller structure. 
In pro-MMP-2, the PEX domain interacts with the C-terminal domain of TIMP-2 (Tissue 
Inhibitors of Matrix MetalloProteinase-2 (Brew & Nagase, 2010)) which allowed the complex 
to tether to plasma membrane through interaction of the N-terminal part of the inhibitor to a 
MT1-MMP homodimer: one molecule of MT1-MMP acting as a docking molecule, the other 
catalyzing pro-MMP-2 activation (Itoh et al., 2006, 2011; Sato & Takino, 2010).  
Of note, this PEX domain also reacts with TIMP-3 and TIMP-4 but no MMP-2 activation was 
noted in such case.  
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It needs to be emphasized that interaction of PEX domain in MMP-2 with MT3-MMP also 
leads to enzyme activation that can be enhanced by the prior binding of pro-MMP-2 to 
chondroitin-4 sulfate chains-containing proteoglycan. PEX domain of MMP-2 was also 
reported to bind to v3, CC chemokine as monocyte chemoattractant protein-3 (MCP-3), 
CXC chemokine as stromal cell derived factor-1 (SDF-1) and fibrinogen. 
Such PEX domain is also important in driving the pro-MMP-9 activation; in human 
neutrophils formation of pro-MMP-9-lipocalin complex favours enzyme activation by 
kallikrein. It is also important for localizing the enzyme at the cell periphery through 
interaction with low density lipoprotein-receptor related protein (LRP), CD-91 or different 
isomer forms of CD-44, protein Ku, and is involved in the formation of covalent complexes 
with proteoglycans (Malla et al., 2008; Monferran et al., 2004).  
An important property of this carboxy terminal domain, in association with an 
unstructured, hydrophilic and flexible long-O-glycosylated domain (OG) in pro-MMP-9 
which contains 11 repeats of the sequence T/SXXP (Figure 2), relies on its ability to catalyze 
the intracellular formation of enzyme dimers (Van den Steen et al., 2001). Importantly, the 
dimer form of pro-MMP-9 is more resistant to MMP-3 activation.  
Gelatinases also appear unique in MMP family in exhibiting fibronectin type II domains 
which are also designated as collagen binding domains (CBD) (Shipley et al., 1996). Indeed, 
deletion of these domains in both enzymes led to protease devoided of collagen(s)- 
gelatin(s)- or elastin-degrading capacity (Allan et al., 1995). Recent data also indicated that 
OG could also mediate MMP-9 gelatin interaction by allowing the independent movement 
of enzyme terminal domain (Vandooren et al., 2011). 
3. Design of MMP inhibitors (MMPI) 
Up to now, a myriad of MMPI has already been synthesized (Table 3).  
The most important studies focus on the combinations of diverse structural modifications; 
three classes of compounds have been developed: combined inhibitors, right hand side and 
left hand side inhibitors based on the scissile bond in the catalytic site (Skiles et al., 2004; 
Whittaker et al., 1999). Some of them have been used as potential therapeutic agents to limit 
tumor progression. Instead of using MMP inhibitors as therapeutic treatment, they might be 
also useful as preventive drugs or as biomarkers in early stage of cancer. Up to now, most of 
the clinical trials in cancer were rather disappointing (Abbenante & Fairlie, 2005; Dormán et 
al., 2010; Fingleton, 2007; Gialeli et al. 2011). 
The first generation of MMPI was based on peptidomimetic skeleton containing a succinic 
acid motif and a hydroxamic acid as zinc binding group (ZBG) (batimastat®, marimastat®, 
solimastat®, galardin®, trocade®). Hydroxamic acid is a bidentate chelator, but it has also a 
good binding affinity to other ions (Cu2+, Fe2+ and Ni2+). They are broad spectrum inhibitors 
and led to musculoskeletal syndrome side effect mainly due to the presence of hydroxamic 
acid. 
Prinomastat® contains a ring embedded sulfo-succinic acid motif, which increases oral 
availability and water solubility. Nevertheless, clinical trials have been discontinued after 
phase III for musculoskeletal toxicity and poor survival rate. 
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Tanomastat® has a thioether function increasing the oral activity and selectivity for MMP-2, 
MMP-3 and MMP-9. Unfortunately, clinical trials are discontinued for haematological 
toxicity and poor survival rate. 
 
MMP 
Inhibitors 
Indication 
Clinical trials
development 
Structure 
Batimastat® 
(BB-94) 
British Biotech 
Cancer 
Broad spectrum 
(MMP-1, -2, -3, -7, -9) 
Phase I 
(Discontinued)
N
H
H O
O
H
N
O
N
H
O
S
S
 
Marimastat® 
(BB-2516) 
British Biotech 
Cancer 
Broad spectrum 
(MMP-1, -2, -7, -9) 
Phase III 
(Discontinued) N
H
H O
O
H
N
O
N
H
O
O H
 
Solimastat® 
(BB-3644) 
British Biotech 
Cancer 
Broad spectrum (MMP-
1, -7) 
Phase I 
(Discontinued) NH
H O
O
H
N
O
N
H
O
N
O
 
Galardin® 
(GM-6001) 
Glycomed 
Eye disease, COPD 
Broad spectrum 
(MMP-1, -2, -9, -12) 
Phase I 
(Discontinued)
N
H
H O
O
H
N
O
N
H
O
N
H  
Prinomastat® 
(AG-3340) 
Agouron 
Cancer 
Macular degeneration 
Broad spectrum 
(MMP-2, -3, -7, -9, -13) 
Phase III 
(Discontinued)
 
N
S
H
N
O
HO
S
O
O
O  
Trocade® 
(Ro32-3555) 
Roche 
Rheumatoid arthritis 
(MMP-1, -8, -13) 
Phase III 
(Discontinued)
 
N
H
H O
O
N
O
N
N
H
O
O
 
Tanomastat® 
(BAY 12-9566) 
Bayer 
Cancer 
Arthritis 
(MMP-2, -3, -8, -9) 
Phase II 
Phase III 
(Discontinued)
O
S
O O H
C l
 
Rebimastat® 
(BMS-275291) 
Bristol-Myers 
Squibb 
Cancer 
Broad spectrum 
(MMP-1, -2, -7, -9, -14) 
Phase III 
(Discontinued) N
H
O
H
N
O
N
H
O
S H
N
N
O
O
 
Metastat® 
(CMT-3) 
Collagenex 
Cancer 
(MMP-2, -9) 
Phase II 
O O H O
N H 2
O
O H
H H
O H
 
Table 3. Main MMPI in clinical development. 
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The thiol zinc binding group of rebimastat® is a weak monodentate ligand and the 
musculoskeletal toxicity and its poor response led clinicians to stop treatment. 
Finally, metastat® is a second generation of tetracyclines still in phase II clinical trials (Acne, 
AIDS-related Kaposi’s sarcoma and mainly used in cancer). The only detected side effect is 
its photosensibility. This inhibitor is selective of MMP-2 and MMP-9 and crosses the blood-
brain barrier. Actually, it is the most promising MMPI. 
These failures are mainly due to their broad spectrum MMP inhibitory activity, the 
similarity of their active sites with those of other metalloproteinases (ADAM, ADAMT…), 
the poor selectivity of the chelating group, the administration of MMPI in late disease stage, 
their poor pharmacokinetics, unavoidable side effects (musculoskeletal pain), toxicity and 
limited oral bioavailability.  
However, these efforts led to pinpoint the importance of MMPI selectivity and allowed the 
identification of MMP as target and anti-target in various diseases progression (Overall & 
Kleifeld, 2006). Certain MMP are both targets and anti-targets depending on the stage of the 
disease. 
4. Galardin® pharmacomodulation as a tool for designing specific 
gelatinases inhibitors  
For a decade, we have been involved in the pharmacomodulation of galardin®, a powerful 
broad spectrum MMPI (Figure 3).  
H O
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N
N
H
M e
O
O
N
H
O
S '1
S '3
S '2
Z n 2 +
G a la rd in ®
Z B G
H
N
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N
H
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P '2
P '3
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A n ch or to o th e r ta r g e t
A na lo g ue s  
Fig. 3. Galardin® and analogues. 
By the beginning of 1994, galardin® was in phase I clinical trials for age related macular 
degeneration (ARMD) and as chronic obstructive pulmonary disease (COPD) by Glycomed.  
In order to increase selectivity, the synthesis of analogues of galardin®, has been achieved. 
The modifications have been focused on the P’1, P’2, P’3 groups and ZBG. 
4.1 Influence of the S’1 subsite: Modulation of galardin
®
 in gelatinases inhibition  
Our first experiments started with the insertion of one unsaturation in P’1 position to 
increase the hydrophobicity of the new compounds and to study the effect of substitution on 
S’1 pocket specificity (Figure 4). For this purpose, replacement of isobutyl group by an 
isobutylidene group of E geometry enhanced by 100-fold MMP-2 selectivity versus MMP-3 
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(IC50 = 1.3 and 179 nM, respectively) (Marcq et al., 2003). The double bond geometry was 
found important for potency and selectivity as shown with the equimolar E/Z mixture 
which displayed lower activity.  
Pursuing these pharmacomodulations aiming at better MMP-2 selectivities, we planned to 
increase hydrophobicity and rigidity with the dehydro and didehydro analogues which 
were synthesized (analogue 2a-d and 3a-h). 
HO
N
H
H
N
N
H
Me
O
O
N
H
O
R
H
N
N
H
Me
O
O
N
H
O
P'1
R = -NH-OH
P'1 = -(CH2)5-CH3, -(CH2)2-Ph,
-CH=CH-Me, -CH=CH-Ph
1
2a-d
3a-h R = -OH
P'1 = -(CH2)n-CH3  
Fig. 4. Pharmacomodulation of the P’1 group. 
Introduction of either one or two unsaturations decreased their potent MMP inhibitory 
activity as compared to parent molecule over all MMP (Moroy et al., 2007). However, the 
presence of a phenyl group at the end of alkyl chain (2b and 2d) led to inhibitors with a 
good activity and selectivity for MMP-9 (IC50 = 38 and 45 nM, respectively). 
In parallel, C7 long alkyl chain containing galardin® 2a displayed a MMP-2 selectivity 
comparing to MMP-9 (IC50 = 123 nM) (Table 4). 
 
Compounds ZBG P’1 MMP-1 MMP-2 MMP-9 MMP-14 
Galardin® -NH-OH  1.5 1.1 0.5 13.4 
1 -NH-OH -iPr 18 9.2 17 10 
2a -NH-OH -(CH2)5-Me 32000 123 > 104 2660 
2b -NH-OH -(CH2)2-Ph 9130 280 45 53100 
2c -NH-OH -CH=CH-Me 984 78500 974 913 
2d -NH-OH -CH=CH-Ph 1240 120 38 2490 
3a -OH -(CH2)6-Me > 105 7570 838 > 105 
3b -OH -(CH2)7-Me > 105 458 241 > 105 
3c -OH -(CH2)8-Me > 105 247 173 > 105 
3d -OH -(CH2)9-Me > 105 249 450 > 105 
3e -OH -(CH2)10-Me > 105 351 211 > 105 
3f -OH -(CH2)11-Me > 105 655 673 > 105 
3g -OH -(CH2)14-Me > 105 762 582 > 105 
3h -OH -(CH2)18-Me > 105 > 105 > 105 > 105 
Table 4. Influence of the P’1 chain length on the selectivity and potency of MMP inhibitors. 
IC50 values are expressed in nM. 
AutoDock 4.0 program (Huey et al., 2007; Morris et al., 1998) was used to perform the 
computational molecular docking. AutoDockTools package was employed to prepare the 
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input files necessary to the docking procedures and to analyze the docking results. The 
figures have been done using Pymol program (DeLano, W. L. 2002. PyMol Molecular 
Graphics System, Palo Alto, CA. http://www.pymol.org). 
Molecular modelling experiments confirmed the importance of the insertion of the alkyl 
chains in the S’1 pocket, supporting the observed biological data for 2a (Figure 5).  
 
Fig. 5. Complex between MMP-2 and analogue 2a. The MMP-2 secondary structure was 
represented in cartoon. The analogue 2a is shown with sticks in which the C atoms are 
colored in magenta. Zn atom is displayed as a grey sphere. 
The S’1 pocket of MMP-2 is sufficiently deep to accommodate the long alkyl chain. On the 
contrary, the S’1 pocket of MMP-9 at the end of the tunnel is restrained, like a funnel by the 
amino acid residues Glu233, Arg241, Thr246 and Pro247. The S’1 pocket of MMP-9 is large 
enough to accept a phenyl group at the entrance of the pocket such as compounds 2b and 
2d. 
In order to increase hydrophobicity, aiming at a better MMP-2 selectivity, the alkyl chain 
was elongated with n = 8 to 20 carbon atoms as described in the literature (Levy et al., 1998; 
Miller et al., 1997; Whittaker et al., 1999). Using galardin® as template, the activity and 
selectivity were not really increased with the length of the linear chain. Batimastat® 
inhibitors increase activity for MMP-2 with C8 long alkyl chain (IC50 = 0.6 nM) and a C12 
analogue displays a MMP-2 selectivity comparing to MMP-1 (IC50 = 1 and 50000 nM, 
respectively). Finally, a good activity for MMP-2 is obtained for C9 long chain marimastat® 
analogues (IC50 < 0.15 nM) and a maximal selectivity occurs with a C16 for MMP-2 versus 
MMP-1 (IC50 = 0.6 and 5000 nM, respectively). 
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Nevertheless, in our case no better IC50 were found for MMP-2 with increasing chain length 
when an unsaturation was incorporated. However, a good selectivity for MMP-2 versus 
MMP-1 and MMP-14 is observed. Also, carboxylic derivatives 3c and 3e displayed a good 
selectivity for MMP-9 versus MMP-1 and MMP-14. 
As stated previously, S’1 pocket is generally quite large in all MMP. However, the amino 
acid residue Arg214 redefines the bottom of the pocket in MMP-1 leading to a small and 
restricted S’1 pocket. The amino acid residue Arg214 can be flexible but in most cases, a 
large P’1 group inhibitor is expected to bind weakly to MMP-1. Thus, it is not surprising, to 
find that most of the MMP-1 inhibitors have relatively small P’1 groups. 
MMP-14 appears as one key-proteolytic enzyme to promote cancer invasion and metastasis 
(Hernandez-Barrantes et al., 2002). Up to now, only one pentacyclic sterol sulphate MMP-14 
inhibitor was described to display MMP-14 selectivity while it exhibits only low potency 
(Fujita et al., 2001).  
S’1 pocket of MMP-14 was found to be two amino acid residues longer than those of 
gelatinases. The amino acid residue Met237 allows favourable interactions with the 
hydrophobic substituents at the bottom of the pocket, but unfavourable interaction with the 
positively charged substituents.  
Therefore, lack of inhibition of this enzyme by long alkyl chain (Table 4) is rather surprising. 
The unsaturation might disturb the entrance of the S’1 pocket, but that is purely speculative. 
Finally, it seems to be more difficult to fit MMP-14 pockets, perhaps in keeping with its 
transmembrane localization and domain structure. 
4.2 Influence of the S’2 subsite on gelatinases inhibition 
Introduction of an alkyl chain in the P’2 position of the indole ring leads to lower gelatinase 
inhibitory activity. Nevertheless, the selectivity for MMP-2 was pinpointed (Marcq et al., 
2003). 
On the contrary, the introduction of a phenyl group at the P’2 position (analogue 4) 
enhanced the selectivity towards MMP-2 maintaining a high potency (IC50 = 0.092 nM). To 
the best of our knowledge, the large and solvent-exposed S’2 pocket could accommodate 
large and hydrophobic groups (LeDour et al., 2008). A good activity was found for MMP-1 
and MMP-14 (IC50 = 0.244 and 0.601 nM, respectively). 
4.3 Influence of the unprimed subsites on gelatinases inhibition  
It is well documented that the hydroxamic acid is one of the most powerful ZBG, but its 
toxicity and low bioavailability triggered tremendous efforts to design other ZBG (Jacobsen 
et al., 2007, 2010). Of note, the zing binding group affinity is as follows: hydroxamate > 
retrohydroxamate > sulfhydryl > phosphinate > carboxylate > heterocyclic core. 
Nevertheless, a zinc binding group with lower affinity may be advantageous. 
In this line, we have proposed various hydrazide and sulfonylhydrazide-type functions as 
potential ZBG. The sulfonylhydrazide derivative is responsible for the increased acidity of 
the NH close to SO2 function allowing the H-bond to be formed with the catalytic glutamate 
residue (Augé et al., 2003, 2004). 
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The hydroxamate acts as a bidentate ligand with the zinc ion to form the distorded trigonal-
bipyramidal coordination geometry. With respect to the design of new ZBG, a DFT (Density 
Functional Theory) study revealed different modes of chelation of the sulfonylhydrazide 
group (Rouffet et al., 2009).  
The zinc ion was found to be ligated to three 4-Me-imidazoles used as mimetics of histidine 
imidazole moieties located in the MMP catalytic site in physiological conditions. The 
sulfonylhydrazide group could chelate the zinc ion in two different manners either in a bi- 
or tri-dentate mode.  
In all cases, interaction between 
i. the Zn2+ ion and the sulfonamide nitrogen was observed as well as, 
ii. the Zn2+ ion with the oxygen atom of the sulfonylhydrazide carbonyl.  
In the case of the tridentate mode, the third interaction involves one of the sulfonyl oxygen 
atom and the Zn2+ ion. Consequently, the bidentate conformation was more favourable (4 to 
5 kcal/mol) and the sulfonylhydrazide function seemed to possess ideal zinc binding 
properties and also biodisponibility and stability. 
Following these investigations, the sulfonylhydrazide group was incorporated into the 
galardin® backbone as zinc binding group. Among the synthesized subtituents, the p-
bromobiphenyl group displayed a good potency for MMP-2 (LeDour et al., 2008). Then, 
based on our preliminary results further modifications of the P’1 (long alkyl chain) and the 
P’2 (phenyl group) substituents were introduced to increase the selectivity for MMP-2 
(Figure 6). 
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Fig. 6. Modifications of the P’2 group and sulfonylhydrazide function as ZBG. 
Finally, a high potency for MMP-9 was obtained with the compound 5a (or 5b) with a small 
group such as an isobutyl (Table 5). Introduction of a phenyl group at the position 2 of the 
indole ring did not modify the activity. This could easily be explained taking into account 
the S’2 solvent-exposed pocket. 
 
Compounds R1 MMP-1 MMP-2 MMP-3 MMP-9 MMP-14 
5a H 30 98 5800 3 20000 
5b Ph 350 247 53 18 1237 
Table 5. Influence of the P’2 group and ZBG on the selectivity and potency of MMP 
inhibitors. IC50 values are expressed in nM. 
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Docking studies of 5a confirmed the occupancy of the MMP-9 S’1 pocket by the isobutyl 
group, the S2 subsite by the p-bromobiphenyl group and the chelation of the 
sulfonylhydrazide to the catalytic site (Figure 7). It is known that the amino acid residues 
Glu412 and Asp410, located in the S2 subsite control the selectivity of MMP-2 and MMP-9, 
respectively.  
In MMP-2, the amino acid residue Glu412 is able to form an H-bond with the substrate which 
could not be formed in MMP-9 presenting the amino acid residue Asp410 (Chen et al., 2003).  
In our case, no H-bond can be formed with the hydrophobic p-bromobiphenyl group and 
the compound 5a displayed selectivity for MMP-9. 
 
Fig. 7. Complex between MMP-9 and analogue 5a. The MMP-9 secondary structure was 
represented in cartoon. The analogue 5a is shown with sticks in which the C atoms are 
colored in magenta. Zn atom is displayed as a grey sphere. 
Unfortunately, none of the P’1 (with an unsaturation and long alkyl chain or bulky 
substituent) and P’2 (with a phenyl group) modified galardin® derivatives exhibited 
increased inhibitory capacity and selectivity. Our docking data indicated that these 
compounds adopted a conformation in which sp2-hybridized carbon atom of the alkylidene 
side-chain led to steric hindrance impeding the entrance in the S’1 subsite. Consequently, 
when the S2 pocket is occupied, the primed subsites could not tolerate any large substituent 
and no synergistic effect could be obtained. 
5. Control of elastolytic cascade by oleoyl-galardin
®
  
Elastin degradation is at the genesis of cardiovascular disease as athero-arteriosclerosis and 
aneurysm formation, and pulmonary diseases as chronic obstructive pulmonary disease or 
lung cancer (Moroy et al., 2012; Muroski et al., 2008; Thompson & Parks, 1996).  
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Elastolysis requires the participation of serine- and metallo-elastases (Figure 8) which act 
through proteolytic cascades.  
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Fig. 8. Control of the serine (HLE)- and metallo-elastases (MMP-2, MMP-9) crosstalk in 
elastolysis by double-headed protease-MMP inhibitor (d-hPI). 
Besides, a serine elastase as human leucocyte elastase (HLE) can degrade TIMP, and 
reversely MMP can hydrolyse serine protease inhibitor as 1 proteinase inhibitor (Nunes et 
al., 2011). 
To control elastolysis, we thus attempted to design substances that could interfere with all 
actors of the depicted cascade. For that purpose, long chain-unsaturated fatty acids, as oleic 
acid, have been described to inhibit HLE (Hornebeck et al., 1985; Shock et al., 1990; Tyagi & 
Simon, 1990) and to impede plasmin-mediated prostromelysin-1 activation (Huet et al., 
2004) as well as gelatinases activities (Berton et al., 2001). To that respect, we envisaged the 
synthesis of a double-headed protease-MMP inhibitor (d-hPI) able to block elastase and 
MMP activities. To that end, an oleoyl group was incorporated to galardin® at the P’3 
position (Figure 9) (Moroy et al., 2011).  
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Fig. 9. Double-headed protease-MMP inhibitor (d-hPI). 
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Oleoyl analogues (carboxylic 6 or hydroxamic 7 acids) are more potent than oleic acid to 
inhibit MMP (Table 6). The hydroxamic acid 7 was found to improve the inhibitory capacity 
toward MMP-2 comparing to oleic acid. 
 
Compounds MMP-2 MMP-3 MMP-7 MMP-9 HLE Plasmin 
Oleic acid 4.3 - 6.5 6.4 3.0 3.5 
6 0.5 0.5 0.07 0.7 0.6 0.7 
7 0.1 0.05 0.6 0.04 8.7 8.3 
Table 6. Inhibition of MMP and serine elastases by oleic acid and oleoyl-galardin® 
derivatives. MMP (Kis values are expressed in M), HLE and plasmin (IC50 values are 
expressed in M).  
The molecular docking computations indicated that compound 7 is able to bind MMP-2 
active site and unable to chelate Zn2+ ion in the active site (Figure 10). 
 
 
 
 
Fig. 10. Complex between MMP-2 and analogue 7. The MMP-2 secondary structure was 
represented in cartoon. The analogue 7 is shown with sticks in which the C atoms are 
colored in magenta. Zn atom is displayed as a grey sphere. 
Instead, the hydroxamic acid function forms a salt bridge with the N-terminal end of the 
amino acid residue Tyr110, while the long alkyl chain was inserted into the S’1 pocket as 
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was already demonstrated. The heterocycle is inserted into the S1 subsite where it interacts 
via an H-bond with the carbonyl group of the amino acid residue Ala194 peptide bond. 
We analyzed the inhibitory capacity of oleic acid, analogues 6 and 7 towards HLE and 
plasmin activities. The compound 6 displayed high potency (IC50 = 0.6 M) against HLE, but 
lower inhibition was observed with oleic acid and the analogue 7 (IC50 = 3.0 and 8.7 M, 
respectively). Molecular docking computations indicated that the carboxylic function of 
compound 6 and oleic acid can form a salt bridge with the amino acid residue Arg217, but 
not compound 7 (not shown).  
Almost the same values are found in the same order for the plasmin–mediated pro-MMP-3 
activation. The lowest energy model of oleic acid with the kringle 5 domain is characterized 
by the presence of a salt bridge between the carboxylic function and the amino acid residue 
Arg512 of plasmin (not shown).  
6. Control of gelatinases through impeding enzyme-substrate interaction  
Another approach to control the activity of those enzymes consists in the regulation of 
exosite protein-ligand interaction. To that respect both Fn(II) [or CBD] and PEX domains are 
involved and, in keeping with data presented on Figure 2, blocking either Fn(II) or PEX 
function will prevent the catalytic function of gelatinases on protein substrates selectively. 
For instance, the proteolysis of collagen and elastin might be inhibited while maintaining 
intact the potential of gelatinases to cleave proteoglycans or several growth factors. 
6.1 Fn(II) domains 
Using recombinant Fn(II) domain as bait, a one bead one-peptide combinatorial peptide 
library was screened (Xu et al., 2007). A peptide displaying high sequence identity with the 
segment 715-721 in human 1(I) collagen chain was identified and proved to inhibit by > 
90% gelatinolysis catalyzed by MMP-2 (Xu et al., 2009). 
The unsaturated fatty acid such as oleic acid inhibited MMP-2 with Ki = 4.3 M. Molecular 
modelling studies focus on the interactions localized at two sites on MMP-2: the fatty chain 
filled the S’1 pocket while the carboxylic acid group was exposed to the solvent. This result 
is in agreement with our previous works showing that the S’1 pocket could accommodate 
long alkyl side chains (LeDour et al., 2008; Moroy et al., 2007). The molecular docking 
computations identified the second site of the oleic acid interactions as the 3rd Fn(II) domain. 
The carboxylic acid function interacts via an H-bond with the phenolic group from the 
amino acid residue Tyr381, via a salt bridge with the guanidinium group of the amino acid 
residue Arg385 and via van der Waals interactions with the amino acid residue Leu356 
while the unsaturated bond forms van der Waals interaction with the amino acid residues 
Phe355, Trp374, Tyr381 and Trp387 (Figure 11). 
Another approach could be the use of a more specific inhibitor directed against the 3rd Fn(II) 
domain.  
For this latter, an inhibitor with two carboxyl groups at each end of the alkyl chain should 
be efficient for targeting respectively the amino acid residue Arg385, as it was observed for 
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oleic acid, and the amino acid residue Arg368 that is also present on the rim of the 
hydrophobic pocket.  
Interestingly, in the full MMP-2, the amino acid residue Arg368 forms a salt bridge with the 
amino acid residue Asp40 belonging to the propeptide domain. According to the binding 
mode of oleic acid, the size of the alkyl chain should be composed by 15 or 16 atoms of 
carbon such as (7Z)-hexadec-7-enedioic acid and (6Z)-pentadec-6-enedioic acid. 
 
 
 
Fig. 11. Complex between MMP-2 and oleic acid. Oleic acid is anchored in the binding 
pocket at the surface of the 3rd Fn(II) domain. 
6.2 Dual occupancy of the enzyme active site and Fn(II) domains 
Another more complex strategy relies on the design of a dual occupancy of the enzyme 
active site and the exosite as Fn(II). That has been originally attempted with a coupled 
hydroxamate-based inhibitor to gelatin-like structures (Jani et al., 2005). No increase in 
selectivity or potency of those compounds towards gelatinases could be attained; it was 
attributed to the possibility that the Fn(II) and catalytic domains of enzyme are tumbling 
independently. 
Thus, we have built a hypothetical inhibitor from the inhibitors previously studied. We have 
added alkyl groups until the hydrophobic pocket of the 3rd Fn(II) was reached: 19 are 
needed to interact with its rims, i.e. the amino acid residues Arg368 and Trp387. If we want 
to reproduce the binding mode of the oleic acid, 32 alkyl groups should be added (Figure 
12). However, the size and the high flexibility of this kind of inhibitor could be problematic. 
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Fig. 12. Hypothetical model of an inhibitor able to bind both the catalytic site and the Fn(II) 
domain of the human MMP-2. The MMP-2 is displayed with its accessible surface area. The 
active site and the binding pocket on the 3rd Fn(II) domain are coloured in orange and in 
cyan, respectively.  
6.3 PEX domains  
Since gelatinases are critically involved in directing cellular invasion, interfering with PEX-
integrins (receptors) interaction might be a nice alternative. As an example, the use of phage 
display identified a peptide that inhibits the association of MMP-9 PEX domain with the 
v5 integrin, preventing proenzyme activation and cell migration (Björklund et al., 2004). 
More recently, a 20 mers peptide encompassing the PEX-binding tail region of C-TIMP-2 
was found to inhibit the membrane-mediated activation in HT-1080 cells (Xu et al., 2011). 
PEX domains play a crucial function in the non proteolytic function of gelatinases. As 
example, the PEX domain of MMP-9 is directly involved in the modulation of epithelial cell 
migration in a transwell chamber assay (Dufour et al., 2008). This domain also promotes B 
cell survival by interacting with 41 and CD-44 receptors (Redondo-Muñoz et al., 2010).  
7. Conclusion 
General considerations need to be pinpointed at aims to give a novel expansion to the 
design of substances able to regulate MMP activity. 
First, MMP as gelatinases are produced by nearly all cell types, but their cellular source may 
intervene in their function and activity. Proteolytic activity liberated by activated 
neutrophils is one pivotal element in the genesis and progression of aneurysms or chronic 
obstructive pulmonary diseases (Muroski et al., 2008; Thompson & Parks, 1996).  
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It has been demonstrated that pro-MMP-9 is produced by neutrophils as a free form i.e. not 
associated with TIMP-1 molecule, more readily activatable by enzyme as stromelysin-1 
(Ardi et al., 2007). In addition, following activation, those cells release extracellular traps i.e. 
neutrophil extracellular traps (NET) formed by the association of chromatin and granule 
proteins; NET are enriched in neutral endopeptidases as neutrophil elastase and MMP-9 
(Brinkmann et al., 2004). To that respect, the use of double-headed (HLE-MMP-9) inhibitors 
as oleoyl-galardin® might be of therapeutic value. Advantageously, as we recently 
documented, oleoyl moiety might be replaced by -lactam (Moroy et al., 2012), a more 
potent and selective HLE inhibitor. 
Although inflammation can orchestrate cancer (Kessenbrock et al., 2010), MMP-2 and MMP-
9 intervene in several other stages of cancer progression. Both enzymes have been involved 
in promoting cell growth; MMP-2 is more linked to cancer cell invasiveness while MMP-9 
may contribute to cell survival.  
Up to now, one selective MMP-9 inhibitor is a monoclonal antibody binding to N-terminal 
part of catalytic domain (Martens et al., 2007). Thus, intuitively, in keeping with those 
distinct functions, the concept of selective inhibitor among gelatinases is emerging.  
Their role in establishing a “metastatic niche” has also been delineated and their 
contribution in angiogenesis has been widely underlined. 
However, paradoxically, MMP-9 can generate either pro- or anti-angiogenic signals 
(Figure 13).  
On one side, it can  
i. regulate VEGF bioavailability for VEGF-R2 receptor (Bergers et al., 2000), 
ii. activate the basic fibroblast growth factor-2 (FGF-2) pathway (Ardi et al., 2009), 
iii. generate elastin fragments i.e. elastokines with potent angiogenic activity (Robinet et al., 
2005). 
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Fig. 13. The paradoxical function of MMP-9 in angiogenesis. 
At the opposite, proteolysis of plasminogen and 3 chain of collagen IV leads to the 
formation of angiostatin and tumstatin (Cornelius et al., 1998; Kessenbrock et al., 2010). 
Importantly, mice deficient in MMP-9 evidenced an increased-tumor growth which was 
attributed to lack of tumstatin formation (Hamano et al., 2003). 
As mentioned, both gelatinases exerted their action at the pericellular environment, 
following binding of their PEX domain to receptors as v3 for MMP-2 or CD-44 for MMP-9. 
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Peptide or chemical libraries can be developed at aims to impede MMP-2(PEX)-v3 or 
MMP-9(PEX)-CD-44 interactions. 
As one example, a bivalent derivatized dilysine tetraamide was isolated which proved to 
interfere with MMP-2/v3 interaction and inhibit angiogenesis (Silletti et al., 2001). 
Possibly, this compound could be chemically modified to confer it additionally MMP-2 
inhibitory activity (Bourguet et al., 2009). 
One main problem related with the control of MMP in general and gelatinases in particular 
relies on the kinetics of production of those enzymes during the cancer course from 
initiation to metastasis formation. In other words, at what stage for one particular type of 
tumor do we need to incorporate MMPI in cancer treatment? 
The development of imaging MMP activity using derivatized selective inhibitor will 
probably answer to this question. Several techniques have been already developed using 
Positron Emission Tomography (PET) with 18F-labelled MMP-2 inhibitor (Furumoto et al., 
2003), Single Photon Emission Computed Tomography (SPECT) with a 123I gelatinases 
inhibitor (Schaffers et al., 2004), or the use of fluorogenic substrates bearing self quenched 
and near infrared FRET pairs (Scherer et al., 2008). 
In our Federal Research Institute (IFR), we aim to develop hybrid nanoprobes build from 
MMPI and fluorescent nanocrystal quantum dots (QDs). Design and chemical synthesis of 
derivatives of galardin®, selective inhibitors of MMP-2, will be followed by their tagging 
with QDs. Photo- and chemical stability of QDs will enable long-term spatiotemporal 
tracking of the process of inhibition of MMP-2 with developed nanoprobe thus permitting 
understanding of physiological process of invasion of melanoma for example. 
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